CoChat
Sign Up
Cited by 223Dupuytren's Contracture and TreatmentsSexual function and dysfunction studiesUrological Disorders and Treatments

Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie’s Disease

Hellstrom, Wayne J.G., Kendirci, Muammer, Matern, Richard, Cockerham, Yolanda, Myers, Leann, Sikka, Suresh C., Venable, Dennis, Honig, Stanton +5 more·2006·Journal of Urology
DOI 10.1016/s0022-5347(06)00517-9
Open this paper in CoChat — free account

Abstract

Purpose We investigated the efficacy and safety of intralesional interferon alpha-2b for the treatment of Peyronie's disease. Materials and methods A total of 117 consecutive patients with a mean age of 55.1 years who had Peyronie's disease were enrolled in a single-blind, multicenter, placebo controlled, parallel study to determine the efficacy and safety of intralesional interferon alpha-2b therapy (Schering, Kenilworth, New Jersey), including 62 who received placebo and 55 who received interferon alpha-2b. Saline (10 ml) in controls and interferon alpha-2b (5 x 10(6) U) were administered biweekly for 12 weeks. Each patient was evaluated for penile curvature, plaque size and density, penile pain, erectile function and penile hemodynamics before and after study completion. Improvement in these parameters was statistically compared between the groups. Results A total of 53 patients in the control arm and 50 in the interferon alpha-2b arm completed the study. Improvement in penile curvature, plaque size and density, and pain resolution was significantly greater in patients treated with interferon alpha-2b vs placebo. The increase in mean International Index of Erectile Function scores was not significantly different between the groups. Penile blood flow improvement was observed in interferon alpha-2b treated patients but not in those who received placebo. The decrease in the number of penile vascular pathologies was significantly higher in interferon alpha-2b cases. Side effec…

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(06)00517-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Interferon is an intralesional therapy that modulates fibroblast proliferation, changing extracellular matrix deposition and collagen production.

    “IFN is another intralesional therapy that modulates fibroblast proliferation leading to a change in extracellular matrix deposition and collagen production.”

    From Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation. (2021) · cites this paper as [37]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hellstrom, W. J. G., Kendirci, M., Matern, R., Cockerham, Y., Myers, L., Sikka, S. C., Venable, D., Honig, S., McCullough, A., Hakim, L. S., Nehra, A., Templeton, L. E., & Pryor, J. L.
Affiliations
  • Tulane University (US)
  • Louisiana State University (US)
  • University of Connecticut (US)
  • New York University (US)
  • Cleveland Clinic Florida (US)
  • Mayo Clinic (US)
  • Rapides Regional Medical Center (US)
  • University of Minnesota (US)
ORCID
Venue
Journal of Urology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-07
Volume
176
Issue
1
Pages
394-398
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
DOI
10.1016/s0022-5347(06)00517-9
OpenAlex
W1971465828
Cited by
223
References
1
Citations by year
2026: 6 · 2025: 8 · 2024: 8 · 2023: 13 · 2022: 8 · 2021: 10 · 2020: 14 · 2019: 9 · 2018: 14 · 2017: 9 · 2016: 20 · 2015: 15 · 2014: 12 · 2013: 14 · 2012: 10
FWCI
7.22
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Journal of Urology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Urology › Urological Disorders and Treatments
Keywords
Peyronie's disease, interferon alfa-2b, intralesional injection, penile curvature, penile plaque, penile pain, erectile function, penile blood flow, minimally invasive therapy, treatment safety, flu-like symptoms
MeSH terms
Interferon alpha-2, Adult, Aged, Humans, Male, Middle Aged, Pain, Penile Erection, Penile Induration, Penis, Recombinant Proteins, Sodium Chloride, Injections, Intralesional, Single-Blind Method, Interferon-alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review